Activated protein C and acute kidney injury: Selective targeting of PAR-1.

Protein C is a plasma serine protease that when activated plays a central role in modulating the function of the vascular endothelium and its interface with the innate immune system. Activated protein C (APC) has a dual mechanism of action via the feedback inhibition of thrombin generation, and as an agonist of protease activated receptor-1 (PAR-1). Through different cofactor interactions, this dual mechanism of antithrombotic and cytoprotective activity results in the ability of APC to modulate endothelial dysfunction by blocking cytokine signaling, functional cell adhesion expression, vascular permeability, apoptosis, and modulating leukocyte migration and adhesion. Deficiency in protein C, which occurs during systemic inflammatory activation, is highly associated with organ dysfunction. APC has shown efficacy in a number of preclinical models of thrombosis and ischemia, and the recombinant human APC drotrecogin alfa (activated), reduces mortality in patients with high-risk severe sepsis. The ability of APC to suppress pro-inflammatory pathways and enhance cellular survival suggests that APC plays a key role in the adaptive response to protect the vessel wall from insult and to enhance endothelial, cellular, and organ survival. The focus of this review will be to summarize the emerging data suggesting the potential therapeutic benefit of APC and related members of the pathway in the prevention and treatment of acute kidney injury.

[1]  José A Fernández,et al.  Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant. , 2009, Blood.

[2]  C. Esmon,et al.  Endogenous activated protein C signaling is critical to protection of mice from lipopolysaccaride‐induced septic shock , 2009, Journal of thrombosis and haemostasis : JTH.

[3]  José A Fernández,et al.  Endogenous EPCR/aPC-PAR1 signaling prevents inflammation-induced vascular leakage and lethality. , 2009, Blood.

[4]  C. Ince,et al.  Activated protein C restores kidney function in endotoxin-induced acute renal failure in the rat , 2009, Critical Care.

[5]  B. Molitoris,et al.  Soluble thrombomodulin protects ischemic kidneys. , 2009, Journal of the American Society of Nephrology : JASN.

[6]  B. Grinnell,et al.  Distinct functions of activated protein C differentially attenuate acute kidney injury. , 2009, Journal of the American Society of Nephrology : JASN.

[7]  U. Bothner,et al.  Epidemiology of acute renal failure and outcome of haemodiafiltration in intensive care , 1997, Intensive Care Medicine.

[8]  Jonathan Himmelfarb,et al.  Acute kidney injury increases risk of ESRD among elderly. , 2009, Journal of the American Society of Nephrology : JASN.

[9]  W. Ruf,et al.  Activated protein C in sepsis: the promise of nonanticoagulant activated protein C , 2008, Current opinion in hematology.

[10]  P. Marsden,et al.  Activated protein C and diabetic nephropathy. , 2008, The New England journal of medicine.

[11]  R. Bellomo,et al.  Potential interventions in sepsis-related acute kidney injury. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[12]  Y. Yuzawa,et al.  Intrarenal administration of recombinant human soluble thrombomodulin ameliorates ischaemic acute renal failure. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[13]  L. O'Brien,et al.  Negative Regulation of Inducible Nitric-oxide Synthase Expression Mediated through Transforming Growth Factor-β-dependent Modulation of Transcription Factor TCF11* , 2007, Journal of Biological Chemistry.

[14]  L. O'Brien,et al.  Activated Protein C Decreases Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand by an EPCR- Independent Mechanism Involving Egr-1/Erk-1/2 Activation , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[15]  B. Molitoris,et al.  Multi-photon microscopy: Linking drug mechanism to disease physiology , 2007 .

[16]  J. Vincent,et al.  Beneficial effects of recombinant human activated protein C in a ewe model of septic shock* , 2007, Critical care medicine.

[17]  C. Esmon,et al.  Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis , 2007, Nature Medicine.

[18]  S. Lowry,et al.  ACTIVATED PROTEIN C SUPPRESSES ADRENOMEDULLIN AND AMELIORATES LIPOPOLYSACCHARIDE-INDUCED HYPOTENSION , 2007, Shock.

[19]  Nigel Mackman,et al.  Endotoxemia and sepsis mortality reduction by non-anticoagulant–activated protein C , 2007, The Journal of experimental medicine.

[20]  B. Molitoris,et al.  Activated protein C ameliorates LPS-induced acute kidney injury and downregulates renal INOS and angiotensin 2. , 2007, American journal of physiology. Renal physiology.

[21]  K. Reinhart,et al.  Protein C Concentrations Correlate with Organ Dysfunction and Predict Outcome Independent of the Presence of Sepsis , 2007, Anesthesiology.

[22]  M. Cohen,et al.  Acute Traumatic Coagulopathy: Initiated by Hypoperfusion: Modulated Through the Protein C Pathway? , 2007, Annals of surgery.

[23]  T. van der Poll,et al.  Recombinant human activated protein C inhibits local and systemic activation of coagulation without influencing inflammation during Pseudomonas aeruginosa pneumonia in rats , 2007, Critical care medicine.

[24]  J. Griffin,et al.  The cytoprotective protein C pathway. , 2007, Blood.

[25]  M. Okusa,et al.  Pharmacologic treatment of acute kidney injury: why drugs haven't worked and what is on the horizon. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[26]  G. Sandusky,et al.  Role of protein C in renal dysfunction after polymicrobial sepsis. , 2007, Journal of the American Society of Nephrology : JASN.

[27]  F. Castellino,et al.  Acute inflammation is exacerbated in mice genetically predisposed to a severe protein C deficiency. , 2007, Blood.

[28]  N. Mackman,et al.  Tissue factor deficiency and PAR-1 deficiency are protective against renal ischemia reperfusion injury. , 2007, Blood.

[29]  P. Kimmel,et al.  Elevated plasma concentrations of IL-6 and elevated APACHE II score predict acute kidney injury in patients with severe sepsis. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[30]  Mark D. Williams,et al.  IN PATIENTS WITH SEVERE SEPSIS, RENAL DYSFUNCTION IS PREDICTED BY SEVERE PROTEIN C DEFICIENCY, WHICH IS IMPROVED BY DROTRECOGIN ALFA ACTIVATED THERAPY.: 368 , 2006 .

[31]  Z. Endre,et al.  Renal endothelial dysfunction and impaired autoregulation after ischemia-reperfusion injury result from excess nitric oxide. , 2006, American journal of physiology. Renal physiology.

[32]  Mihwa Kim,et al.  Association between Increases in Urinary Neutrophil Gelatinase–associated Lipocalin and Acute Renal Dysfunction after Adult Cardiac Surgery , 2006, Anesthesiology.

[33]  V. Mai,et al.  Urinary neutrophil gelatinase-associated lipocalcin in D+HUS: a novel marker of renal injury , 2006, Pediatric Nephrology.

[34]  L. King,et al.  Keratinocyte-derived chemokine is an early biomarker of ischemic acute kidney injury. , 2006, American journal of physiology. Renal physiology.

[35]  A. Jevnikar,et al.  Nitric oxide induces apoptosis in renal tubular epithelial cells through activation of caspase-8. , 2006, American journal of physiology. Renal physiology.

[36]  Jonathan Himmelfarb,et al.  Incidence and mortality of acute renal failure in Medicare beneficiaries, 1992 to 2001. , 2006, Journal of the American Society of Nephrology : JASN.

[37]  E. McCarthy,et al.  Declining mortality in patients with acute renal failure, 1988 to 2002. , 2006, Journal of the American Society of Nephrology : JASN.

[38]  S. Shams,et al.  Effects of Co-Administration of an iNOS Inhibitor with a Broad-Spectrum Reactive Species Scavenger in Rat Renal Ischemia/Reperfusion Injury , 2006, Nephron Experimental Nephrology.

[39]  A. Solà,et al.  NO and NOS isoforms in the development of apoptosis in renal ischemia/reperfusion. , 2006, Free radical biology & medicine.

[40]  R. L. Grubbs,et al.  FoxA2 Involvement in Suppression of Protein C, an Outcome Predictor in Experimental Sepsis , 2006, Clinical and Vaccine Immunology.

[41]  M. Okusa,et al.  Acute kidney injury associated with cardiac surgery. , 2005, Clinical journal of the American Society of Nephrology : CJASN.

[42]  L. O'Brien,et al.  Activated protein C and sepsis. , 2006, Frontiers in bioscience : a journal and virtual library.

[43]  J. Megyesi,et al.  Disruption of renal peritubular blood flow in lipopolysaccharide-induced renal failure: role of nitric oxide and caspases. , 2005, American journal of physiology. Renal physiology.

[44]  Joseph V Bonventre,et al.  Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. , 2005, Journal of the American Society of Nephrology : JASN.

[45]  James A Russell,et al.  Early changes in organ function predict eventual survival in severe sepsis* , 2005, Critical care medicine.

[46]  José A Fernández,et al.  Activated Protein C Reduces Graft Neutrophil Activation in Clinical Renal Transplantation , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[47]  C. Esmon Is APC activation of endothelial cell PAR1 important in severe sepsis?: No , 2005, Journal of thrombosis and haemostasis : JTH.

[48]  J. Planquois,et al.  New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated) , 2005, Critical care.

[49]  W. Macias,et al.  Activated Protein C , 2005 .

[50]  J. Vincent,et al.  Has mortality from acute renal failure decreased? A systematic review of the literature. , 2005, The American journal of medicine.

[51]  B. Dahlbäck,et al.  The anticoagulant protein C pathway , 2005, FEBS letters.

[52]  B. Molitoris,et al.  Intravital multiphoton microscopy of dynamic renal processes. , 2005, American journal of physiology. Renal physiology.

[53]  R. Bellomo,et al.  Renal blood flow in sepsis , 2005, Critical care.

[54]  J. Garcia,et al.  Activated Protein C Mediates Novel Lung Endothelial Barrier Enhancement , 2005, Journal of Biological Chemistry.

[55]  C. Feistritzer,et al.  Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. , 2005, Blood.

[56]  Jonathan Himmelfarb,et al.  Sepsis and the kidney. , 2005, Critical care clinics.

[57]  Kumar Sharma,et al.  Multiple Metabolic Hits Converge on CD36 as Novel Mediator of Tubular Epithelial Apoptosis in Diabetic Nephropathy , 2005, PLoS medicine.

[58]  B. Dahlbäck,et al.  Selective modulation of protein C affinity for EPCR and phospholipids by Gla domain mutation , 2004, The FEBS journal.

[59]  T. A. Sutton,et al.  Minocycline reduces renal microvascular leakage in a rat model of ischemic renal injury. , 2005, American journal of physiology. Renal physiology.

[60]  Jerry A Nick,et al.  Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. , 2004, Blood.

[61]  H. Sarau,et al.  Angiotensin II Induces Neutrophil Accumulation In Vivo Through Generation and Release of CXC Chemokines , 2004, Circulation.

[62]  D. P. Bota,et al.  Epidemiology and Outcome in Renal Failure , 2004, The International journal of artificial organs.

[63]  R. Quigg,et al.  Acute Renal Failure in Endotoxemia is Dependent on Caspase Activation , 2003 .

[64]  Ching-mei Hsu,et al.  INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITOR REVERSES EXACERBATING EFFECTS OF HYPERTONIC SALINE ON LUNG INJURY IN BURN , 2004, Shock.

[65]  J. Ganopolsky,et al.  A protein C deficiency exacerbates inflammatory and hypotensive responses in mice during polymicrobial sepsis in a cecal ligation and puncture model. , 2004, The American journal of pathology.

[66]  B. Molitoris,et al.  Endothelial injury and dysfunction: role in the extension phase of acute renal failure. , 2004, Kidney international.

[67]  R. Schrier,et al.  Acute renal failure and sepsis. , 2004, The New England journal of medicine.

[68]  R. L. Grubbs,et al.  Evaluation of protein C and other biomarkers as predictors of mortality in a rat cecal ligation and puncture model of sepsis* , 2004, Critical care medicine.

[69]  R. Schrier,et al.  Acute renal failure: definitions, diagnosis, pathogenesis, and therapy. , 2004, The Journal of clinical investigation.

[70]  D. Nelson,et al.  Leukocyte and endothelial cell interactions in sepsis: Relevance of the protein C pathway , 2004, Critical care medicine.

[71]  D. Nelson,et al.  Severe protein C deficiency predicts early death in severe sepsis , 2004, Critical care medicine.

[72]  D. Batlle,et al.  Increased ACE 2 and Decreased ACE Protein in Renal Tubules From Diabetic Mice: A Renoprotective Combination? , 2004, Hypertension.

[73]  D. Inthorn,et al.  Microhemodynamic and cellular mechanisms of activated protein C action during endotoxemia* , 2004, Critical care medicine.

[74]  S. Calvano,et al.  Effects of Drotrecogin Alfa (Activated) in Human Endotoxemia , 2004, Shock.

[75]  E. Mazzon,et al.  Effects of GW274150, a novel and selective inhibitor of iNOS activity, in acute lung inflammation , 2004, British journal of pharmacology.

[76]  J. Bakker,et al.  Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock* , 2004, Critical care medicine.

[77]  C. Ahn,et al.  Inducible nitric oxide synthase inhibitors prolonged the survival of skin xenografts through selective down-regulation of pro-inflammatory cytokine and CC-chemokine expressions. , 2003, Transplant immunology.

[78]  P. Ward,et al.  The enigma of sepsis. , 2003, The Journal of clinical investigation.

[79]  J. Griffin,et al.  Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor. , 2003, The Biochemical journal.

[80]  A. Ahluwalia,et al.  Protection against lipopolysaccharide‐induced endothelial dysfunction in resistance and conduit vasculature of iNOS knockout mice , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[81]  Mitchell M. Levy,et al.  2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference , 2003, Intensive Care Medicine.

[82]  G. Bernard,et al.  Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial* , 2003, Critical care medicine.

[83]  José A Fernández,et al.  Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective , 2003, Nature Medicine.

[84]  T. Bártfai,et al.  Enhanced chemokine response in experimental acute Escherichia coli pyelonephritis in IL‐1β‐deficient mice , 2003, Clinical and experimental immunology.

[85]  J. Helterbrand,et al.  Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis , 2003, Critical care medicine.

[86]  B. Molitoris,et al.  Microvascular endothelial injury and dysfunction during ischemic acute renal failure. , 2002, Kidney international.

[87]  W. Buurman,et al.  Apoptosis and inflammation in renal reperfusion injury , 2002, Transplantation.

[88]  W. Ruf,et al.  Activation of Endothelial Cell Protease Activated Receptor 1 by the Protein C Pathway , 2002, Science.

[89]  M. Goligorsky,et al.  Nitric oxide in acute renal failure: NOS versus NOS. , 2002, Kidney international.

[90]  T. Slowinski,et al.  Association of Factor V Leiden Mutation with Delayed Graft Function, Acute Rejection Episodes and Long-term Graft Dysfunction in Kidney Transplant Recipients , 2002, Thrombosis and Haemostasis.

[91]  Y. Yuzawa,et al.  Effects of human soluble thrombomodulin on experimental glomerulonephritis. , 2002, Kidney international.

[92]  M. Wolzt,et al.  Adrenoceptor Hyporeactivity Is Responsible for Escherichia coli Endotoxin‐Induced Acute Vascular Dysfunction in Humans , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[93]  D. Remick,et al.  Neutralization of Groα and macrophage inflammatory protein-2 attenuates renal ischemia/reperfusion injury , 2001 .

[94]  J. Egido,et al.  Angiotensin II and renal fibrosis. , 2001, Hypertension.

[95]  R. Wüthrich,et al.  HETEROZYGOSITY FOR THE FACTOR V LEIDEN (G1691A) MUTATION PREDISPOSES RENAL TRANSPLANT RECIPIENTS TO THROMBOTIC COMPLICATIONS AND GRAFT LOSS1 , 2001, Transplantation.

[96]  F. Castellino Gene targeting in hemostasis: protein C. , 2001, Frontiers in bioscience : a journal and virtual library.

[97]  B. Grinnell,et al.  Recombinant human activated protein C: A system modulator of vascular function for treatment of severe sepsis , 2001, Critical care medicine.

[98]  L. Gelbert,et al.  Gene Expression Profile of Antithrombotic Protein C Defines New Mechanisms Modulating Inflammation and Apoptosis* , 2001, The Journal of Biological Chemistry.

[99]  J. Pfeilschifter,et al.  Nitric oxide induces MIP‐2 transcription in rat renal mesangial cells and in a rat model of glomerulonephritis , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[100]  D. Bouchier-Hayes,et al.  Nitric oxide in unilateral ureteral obstruction: effect on regional renal blood flow. , 2001, Kidney international.

[101]  H. Toga,et al.  INDUCIBLE NITRIC OXIDE SYNTHASE EXPRESSION AND NUCLEAR FACTOR-κB ACTIVATION IN ALVEOLAR TYPE II CELLS IN LUNG INJURY , 2001, Experimental lung research.

[102]  H. Isobe,et al.  Activated Protein C Prevents Endotoxin-Induced Hypotension in Rats by Inhibiting Excessive Production of Nitric Oxide , 2001, Circulation.

[103]  A. Gascoigne,et al.  Circulating endothelial cells in patients with septic shock. , 2001, American journal of respiratory and critical care medicine.

[104]  J. Helterbrand,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis , 2003 .

[105]  D. Remick,et al.  Neutralization of Gro alpha and macrophage inflammatory protein-2 attenuates renal ischemia/reperfusion injury. , 2001, The American journal of pathology.

[106]  C. Esmon The protein C pathway. , 2003, Critical care medicine.

[107]  C. Fisher,et al.  Protein C levels as a prognostic indicator of outcome in sepsis and related diseases , 2000, Critical care medicine.

[108]  K. Pfeffer,et al.  Massive chemokine transcription in acute renal failure due to polymicrobial sepsis. , 2000, Shock.

[109]  T. Noguchi,et al.  Activated protein C reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation. , 2000, Blood.

[110]  B. Dahlbäck,et al.  Factor V R506Q mutation (activated protein C resistance) is an additional risk factor for early renal graft loss associated with acute vascular rejection. , 2000, Transplantation.

[111]  B. Molitoris,et al.  Acute renal failure in the new millennium: time to consider combination therapy. , 2000, Seminars in nephrology.

[112]  C. Esmon,et al.  Endothelial Protein C Receptor , 1999, Thrombosis and Haemostasis.

[113]  C. Esmon,et al.  Regulation and functions of the protein C anticoagulant pathway. , 1999, Haematologica.

[114]  U. Lindauer,et al.  Heparin Inhibits Leukocyte Rolling in Pial Vessels and Attenuates Inflammatory Changes in a Rat Model of Experimental Bacterial Meningitis , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[115]  C. Thiemermann,et al.  Intrarenal haemodynamics and renal dysfunction in endotoxaemia: effects of nitric oxide synthase inhibition , 1997, British journal of pharmacology.

[116]  C. Esmon,et al.  The Protein C Pathway: New Insights , 1997, Thrombosis and Haemostasis.

[117]  M. Nesheim,et al.  The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. , 1996, Blood.

[118]  J. Lefkowith,et al.  GRO chemokines: a transduction, integration, and amplification mechanism in acute renal inflammation. , 1995, The American journal of physiology.

[119]  D. Pittet,et al.  The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. , 1995, JAMA.

[120]  G. D. Young,et al.  Enhancement of tissue plasminogen activator-induced fibrinolysis by activated protein C in endotoxin-treated rabbits. , 1991, The Journal of laboratory and clinical medicine.

[121]  O. Källskog,et al.  Peritubular capillary permeability and intravascular RBC aggregation after ischemia: effects of neutrophils. , 1990, The American journal of physiology.

[122]  A. Driedger,et al.  Vasoactive hormones in the renal response to systemic sepsis. , 1988, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[123]  B. MacLeod,et al.  Sodium nitroprusside-induced hypotension and renal blood flow , 1977, Canadian Anaesthetists' Society journal.

[124]  R. Katz,et al.  A Comparison of the Cardiovascular Effects of Sodium Nitroprusside and Trimethaphan , 1977, Anesthesiology.

[125]  K. Solez,et al.  Medullary plasma flow and intravascular leukocyte accumulation in acute renal failure. , 1974, Kidney international.

[126]  A. Imbriano [Blood coagulation]. , 1955, La Semana medica.